EA200700686A1 - Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии - Google Patents

Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии

Info

Publication number
EA200700686A1
EA200700686A1 EA200700686A EA200700686A EA200700686A1 EA 200700686 A1 EA200700686 A1 EA 200700686A1 EA 200700686 A EA200700686 A EA 200700686A EA 200700686 A EA200700686 A EA 200700686A EA 200700686 A1 EA200700686 A1 EA 200700686A1
Authority
EA
Eurasian Patent Office
Prior art keywords
radioactive isotope
cytotoxic agent
combined therapy
liposomes including
liposomes
Prior art date
Application number
EA200700686A
Other languages
English (en)
Other versions
EA011715B1 (ru
Inventor
Рой Ларсен
Тора Йоханна Йонасдоттир
Original Assignee
Алгета Аса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алгета Аса filed Critical Алгета Аса
Publication of EA200700686A1 publication Critical patent/EA200700686A1/ru
Publication of EA011715B1 publication Critical patent/EA011715B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к цитотоксическим агентам, представляющим собой липосомы, где данные липосомы включают в себя раствор, содержащий по меньшей мере один альфа-излучающий радиоактивный изотоп и по меньшей мере один другой терапевтический агент, в частности химиотерапевтический агент. В данном изобретении также предложены способы получения таких цитотоксических агентов, способы лечения, особенно лечения рака, с использованием данных агентов и способы их применения в изготовлении лекарственных средств.
EA200700686A 2004-10-22 2005-10-21 Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии EA011715B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0423565.1A GB0423565D0 (en) 2004-10-22 2004-10-22 Formulation
PCT/GB2005/004074 WO2006043083A2 (en) 2004-10-22 2005-10-21 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy

Publications (2)

Publication Number Publication Date
EA200700686A1 true EA200700686A1 (ru) 2007-10-26
EA011715B1 EA011715B1 (ru) 2009-04-28

Family

ID=33485085

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700686A EA011715B1 (ru) 2004-10-22 2005-10-21 Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии

Country Status (17)

Country Link
US (1) US20080193374A1 (ru)
EP (1) EP1812115B1 (ru)
JP (1) JP5615483B2 (ru)
KR (2) KR20070108851A (ru)
CN (1) CN101060886A (ru)
AU (1) AU2005297082B2 (ru)
BR (1) BRPI0517006A (ru)
CA (1) CA2583367C (ru)
EA (1) EA011715B1 (ru)
ES (1) ES2424844T3 (ru)
GB (1) GB0423565D0 (ru)
IL (1) IL182634A (ru)
MX (1) MX2007004542A (ru)
NO (1) NO20072529L (ru)
NZ (1) NZ582713A (ru)
WO (1) WO2006043083A2 (ru)
ZA (1) ZA200704035B (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294496T3 (es) 2003-04-30 2008-04-01 Ramot At Tel Aviv University Ltd. Metodo y dispositivo para radioterapia.
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
AU2010272957B2 (en) * 2009-07-17 2016-03-03 Rigshospitalet Loading technique for preparing radionuclide and ionophore containing liposomes in which the ionophore is 2-hydroxyquionoline (carbostyril) or structurally related 2-hydroxyquinolines
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
AU2011344865B2 (en) 2010-12-14 2017-03-09 Rigshospitalet Entrapment of radionuclides in nanoparticle compositions
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
WO2014039874A2 (en) * 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
EP2934545A1 (en) * 2012-12-19 2015-10-28 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
WO2014099056A2 (en) 2012-12-20 2014-06-26 Carnegie Mellon University Methods and materials for reducing organ transplant rejection or ischemic/reperfusion injury in a subject
US10792366B2 (en) 2015-02-19 2020-10-06 Carnegie Mellon University Methods to reduce toxicities and to improve bioavailabilities of nanodrugs
DK3261681T3 (da) * 2015-02-26 2020-04-27 Sciencons AS Radiofarmaceutiske opløsninger med fordelagtige egenskaber
US9433690B1 (en) * 2015-02-26 2016-09-06 Sciencons AS Radiopharmaceutical solutions with advantageous properties
SI3111959T1 (en) * 2015-07-03 2018-04-30 Oncoinvent As Radiotherapeutic particles and suspensions
AU2018265386B2 (en) 2017-05-11 2020-07-23 Alpha Tau Medical Ltd. Polymer coatings for brachytherapy devices
MX2020009940A (es) 2018-04-02 2020-10-16 Alpha Tau Medical Ltd Liberacion controlada de radionucleidos.
WO2022058338A1 (en) * 2020-09-15 2022-03-24 Oncoinvent As Preparations of radium-224 and progenies for use in radionuclide therapy in combination with dna repair inhibitors
US11857803B2 (en) 2020-12-16 2024-01-02 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy with enhanced beta treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
WO2001097859A1 (en) * 2000-06-16 2001-12-27 Sloan-Kettering Institute For Cancer Research Liposomal encapsulation of chelated actinium-225 and uses thereof
US20040166060A1 (en) * 2000-06-16 2004-08-26 Sloan Kettering Institute For Cancer Research Liposomal encapsulation of alpha particle emittors and uses thereof
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US7718160B2 (en) * 2002-07-02 2010-05-18 The Board Of Regents Of The University Of Texas System Radiolabeled compounds and liposomes and their method of making and using same
US7254229B2 (en) * 2003-03-07 2007-08-07 Legerity, Inc. Method and apparatus for an active impedance feedback
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
EA011715B1 (ru) 2009-04-28
JP2008517049A (ja) 2008-05-22
NO20072529L (no) 2007-05-18
WO2006043083A8 (en) 2007-09-27
CA2583367A1 (en) 2006-04-27
IL182634A (en) 2016-03-31
AU2005297082B2 (en) 2011-11-17
US20080193374A1 (en) 2008-08-14
JP5615483B2 (ja) 2014-10-29
WO2006043083A3 (en) 2007-01-04
ES2424844T3 (es) 2013-10-09
MX2007004542A (es) 2007-08-17
EP1812115B1 (en) 2013-05-15
WO2006043083A2 (en) 2006-04-27
BRPI0517006A (pt) 2008-09-30
ZA200704035B (en) 2008-08-27
AU2005297082A1 (en) 2006-04-27
CA2583367C (en) 2014-09-16
IL182634A0 (en) 2007-07-24
EP1812115A2 (en) 2007-08-01
KR20130019029A (ko) 2013-02-25
NZ582713A (en) 2012-06-29
CN101060886A (zh) 2007-10-24
GB0423565D0 (en) 2004-11-24
KR20070108851A (ko) 2007-11-13

Similar Documents

Publication Publication Date Title
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
HK1120427A1 (en) Anti-glypican-3 antibody
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
HK1071310A1 (en) Combination therapy for the treatment of cancer
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DK1965801T3 (da) Kombination af azd2171 og pemetrexed
NO20056171L (no) Kombinasjonsterapi
EA200201068A1 (ru) Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз
IL177953A0 (en) Combination therapy including azd2171 and a taxane
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
MX2007003463A (es) Triciclos, su elaboracion y su uso como agentes farmaceuticos.
MXPA05008879A (es) Una terapia combinada que comprende un derivado de indolopirrolocarbazol y otro agente antitumoral.
DE60308403D1 (de) Kombinationstherapie mit gemzitabin und zd6126

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU